CA2764465C - Glomerulonephritis treatment - Google Patents

Glomerulonephritis treatment Download PDF

Info

Publication number
CA2764465C
CA2764465C CA2764465A CA2764465A CA2764465C CA 2764465 C CA2764465 C CA 2764465C CA 2764465 A CA2764465 A CA 2764465A CA 2764465 A CA2764465 A CA 2764465A CA 2764465 C CA2764465 C CA 2764465C
Authority
CA
Canada
Prior art keywords
compound
group
glomerulonephritis
treatment
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2764465A
Other languages
English (en)
French (fr)
Other versions
CA2764465A1 (en
Inventor
Berit Johansen
Andrea Huwiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AS
Original Assignee
Avexxin AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin AS filed Critical Avexxin AS
Publication of CA2764465A1 publication Critical patent/CA2764465A1/en
Application granted granted Critical
Publication of CA2764465C publication Critical patent/CA2764465C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2764465A 2009-06-04 2010-06-04 Glomerulonephritis treatment Active CA2764465C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0909643A GB0909643D0 (en) 2009-06-04 2009-06-04 Glomerulonephritis treatment
GB0909643.9 2009-06-04
PCT/EP2010/003384 WO2010139482A1 (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Publications (2)

Publication Number Publication Date
CA2764465A1 CA2764465A1 (en) 2010-12-09
CA2764465C true CA2764465C (en) 2018-03-20

Family

ID=40936918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2764465A Active CA2764465C (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Country Status (14)

Country Link
US (3) US20120136066A1 (https=)
EP (2) EP2745837B1 (https=)
JP (1) JP5837481B2 (https=)
AU (1) AU2010256013B2 (https=)
CA (1) CA2764465C (https=)
CY (1) CY1118269T1 (https=)
DK (2) DK2437739T3 (https=)
ES (2) ES2587719T3 (https=)
GB (1) GB0909643D0 (https=)
HU (2) HUE030085T2 (https=)
LT (1) LT2745837T (https=)
PL (2) PL2437739T3 (https=)
PT (2) PT2745837T (https=)
WO (1) WO2010139482A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014633D0 (en) * 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) * 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
EP3515422A1 (en) * 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
EP3638221B1 (en) * 2017-06-16 2021-09-29 Avexxin AS Compositions and methods for treatment of a fibrotic disease
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
JP2000508645A (ja) * 1996-04-12 2000-07-11 ペプテック リミテッド ポリ不飽和脂肪酸を使用する免疫病の治療方法
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6031014A (en) 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
US20100144827A1 (en) * 2006-12-20 2010-06-10 Medwell Laboratories Ltd. C/O Ngt Technological Incubator Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
JP5620272B2 (ja) * 2007-11-09 2014-11-05 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ ＮｏｒｇｅＡＳ 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物

Also Published As

Publication number Publication date
HUE027050T2 (en) 2016-08-29
CA2764465A1 (en) 2010-12-09
JP5837481B2 (ja) 2015-12-24
EP2437739B1 (en) 2015-07-29
PT2437739E (pt) 2015-10-12
DK2437739T3 (en) 2015-08-17
PL2745837T3 (pl) 2017-01-31
US8796251B2 (en) 2014-08-05
ES2587719T3 (es) 2016-10-26
CY1118269T1 (el) 2017-06-28
AU2010256013B2 (en) 2013-05-16
US20120136066A1 (en) 2012-05-31
ES2546198T3 (es) 2015-09-21
EP2745837A1 (en) 2014-06-25
AU2010256013A1 (en) 2012-01-12
JP2012528813A (ja) 2012-11-15
HUE030085T2 (en) 2017-04-28
US20140256824A1 (en) 2014-09-11
PT2745837T (pt) 2016-08-22
US9187396B2 (en) 2015-11-17
EP2745837B1 (en) 2016-07-27
LT2745837T (lt) 2016-10-25
US20100311843A1 (en) 2010-12-09
DK2745837T3 (en) 2016-08-29
WO2010139482A1 (en) 2010-12-09
PL2437739T3 (pl) 2015-11-30
GB0909643D0 (en) 2009-07-22
EP2437739A1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
CA2764465C (en) Glomerulonephritis treatment
AU2011298340B2 (en) Rheumatoid arthritis treatment using polyunsaturated long chain ketones
Lü et al. 3, 4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout
JP6689078B2 (ja) 超高純度なテトラヒドロカンナビノール−１１−酸
JP2006508986A (ja) ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
WO2016159577A2 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
JP7184241B2 (ja) ベンズヒドリルチオアセトアミド化合物を有効成分として含む線維化疾患の治療用組成物
WO2009051909A1 (en) Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
CN102333754A (zh) 洛索洛芬衍生物和含有其的药品
DE19803003A1 (de) 5-Aroylnaphthalinderivate
CN109476611B (zh) 一种卤代化合物及其轴手性异构体
JPH05331129A (ja) カフェー酸誘導体及びそれを含む医薬組成物
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
WO2021104507A1 (zh) 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
Wang et al. Discovery and optimization of ester-linked ibuprofen-glycine hybrids as the NF-κB pathway inhibitors for the treatment of ulcerative colitis
JP2008543741A (ja) 新規な化合物
WO2019159868A1 (ja) 大腸炎改善剤
CN106946851B (zh) 一种用于预防和治疗肾结石的药物
CN115998734A (zh) β-咔啉-1-丙酸在预防和治疗高尿酸血症药物中的应用
CN104592032A (zh) 一类具有2-硝基单边取代的不对称单羰基姜黄素类似物及用途
WO2022121222A1 (zh) 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150528

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241205